CIZUMAB (Bevacizumab)

1.002.00

CIZUMAB (Bevacizumab) is a anti-angiogenic, Anti Neoplastics therapy. It works by selectively blocking a protein called vascular endothelial growth factor (VEGF) to its cell surface receptors. his inhibition leads to a reduction in microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues.

It is used in the treatment of;

  • cancer of colon and rectum,
  • non-small cell lung cancer,
  • renal cell cancer (RCC, a type of cancer that begins in the kidney)
  • glioblastoma (a certain type of cancerous brain tumor)
  • peritoneal (layer of tissue that lines the abdomen) cancer
  • certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (the tube that transports eggs released by the ovaries to the uterus), and cervical cancer (cancer that begins in the opening of the uterus [womb]).

Available in Strengths of 100mg & 400mg

Clear
Enquiry Now

Additional information

Trade Name

CIZUMAB 400

Generic Name

Bevacizumab

Manufacturer

Hetero Healthcare Ltd

Drug Type

Oncology

Indication

cancer of colon and rectum, non-small cell lung cancer, kidney cancer, brain tumor, ovarian cancer and cervical cancer.

Doasage Form

Injectible

Packaging

1 x 16ml /400mg

Strength

100mg, 400mg